Visceral obesity and the role of the somatotropic axis in the development of metabolic complications.
It is well recognized that aberrant fat localization such as visceral obesity rather than total body fat mass is a major risk factor for cardiovascular disease and type 2 diabetes mellitus. During recent decades, several studies have described a range of metabolic disturbances associated with abdominal obesity, including glucose intolerance, hyperinsulinaemia, insulin resistance, hypertension and dyslipoproteinaemia, now widely known as the metabolic syndrome. Several abnormalities in the hypothalamic-pituitary axis have been described associated with visceral obesity, suggesting a central neuroendocrine dysregulation including increased cortisol concentration and impaired gonadotropin and growth hormone (GH) secretion. Some steps in the chain of events in this theory still remain unclear, however, although these findings have introduced new therapeutic possibilities. These include therapy with sex steroids in both viscerally obese men and women, and several attempts to use GH to treat the endocrine abnormalities present in visceral obesity. The results of these studies are promising, but the therapies are still not recommended for general use.
Franco
C
C
Research Centre for Endocrinology and Metabolism, Sahlgrenska University Hospital, Göteborg, Sweden. celina.franco@sahlgrenska.se
Bengtsson
B A
BA
Johannsson
G
G
D000005:Abdomen / Q000473:pathology; D000273:Adipose Tissue / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology / Q000209:etiology; D006065:Gonadotropins, Pituitary / Q000378:metabolism*; D019382:Human Growth Hormone / Q000378:metabolism*; D006801:Humans; D009765:Obesity / Q000150:complications* / Q000473:pathology / Q000503:physiopathology*; D014781:Viscera / Q000473:pathology
D006065:Gonadotropins, Pituitary; D019382:Human Growth Hormone